Lassa Fever - Pipeline Insight, 2025
Description
DelveInsight’s, “Lassa Fever - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Lassa Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Lassa Fever: Overview
Lassa Fever is an acute viral hemorrhagic illness caused by the Lassa virus, which belongs to the Arenaviridae family. The disease is endemic in West African countries, including Nigeria, Sierra Leone, Liberia, and Guinea. Humans typically contract the virus through exposure to food or household items contaminated with urine or feces of infected Mastomys rats, the primary reservoir of the Lassa virus. Person-to-person transmission can also occur through direct contact with the blood, urine, feces, or other bodily secretions of an infected individual, posing significant risks to healthcare workers and those in close contact with infected patients.
The incubation period of Lassa Fever ranges from 6 to 21 days, and its clinical presentation can vary from mild to severe. Early symptoms often include fever, general weakness, and malaise, which can progress to more severe symptoms such as hemorrhaging, respiratory distress, repeated vomiting, facial swelling, pain in the chest, back, and abdomen, and shock. Neurological problems, including hearing loss, tremors, and encephalitis, may also occur in severe cases. The case-fatality rate is approximately 1% overall but can reach 15% among patients hospitalized with severe cases of Lassa Fever. Early supportive care with rehydration and symptomatic treatment improves survival, while the antiviral drug ribavirin has shown effectiveness if administered early in the course of the illness.
Preventing Lassa Fever primarily involves reducing contact with the Mastomys rodent population and implementing effective infection control practices. This includes storing food in rodent-proof containers, maintaining clean households, and using traps to reduce rodent populations. In healthcare settings, strict barrier nursing techniques, such as using protective clothing and proper disposal of medical waste, are crucial to prevent nosocomial infections.
""Lassa Fever- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lassa Fever pipeline landscape is provided which includes the disease overview and Lassa Fever treatment guidelines. The assessment part of the report embraces, in depth Lassa Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lassa Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Lassa Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lassa Fever Emerging Drugs
Further product details are provided in the report……..
Lassa Fever: Therapeutic Assessment
This segment of the report provides insights about the different Lassa Fever drugs segregated based on following parameters that define the scope of the report, such as:
Lassa Fever: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lassa Fever therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lassa Fever drugs.
Lassa Fever Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Lassa Fever: Overview
Lassa Fever is an acute viral hemorrhagic illness caused by the Lassa virus, which belongs to the Arenaviridae family. The disease is endemic in West African countries, including Nigeria, Sierra Leone, Liberia, and Guinea. Humans typically contract the virus through exposure to food or household items contaminated with urine or feces of infected Mastomys rats, the primary reservoir of the Lassa virus. Person-to-person transmission can also occur through direct contact with the blood, urine, feces, or other bodily secretions of an infected individual, posing significant risks to healthcare workers and those in close contact with infected patients.
The incubation period of Lassa Fever ranges from 6 to 21 days, and its clinical presentation can vary from mild to severe. Early symptoms often include fever, general weakness, and malaise, which can progress to more severe symptoms such as hemorrhaging, respiratory distress, repeated vomiting, facial swelling, pain in the chest, back, and abdomen, and shock. Neurological problems, including hearing loss, tremors, and encephalitis, may also occur in severe cases. The case-fatality rate is approximately 1% overall but can reach 15% among patients hospitalized with severe cases of Lassa Fever. Early supportive care with rehydration and symptomatic treatment improves survival, while the antiviral drug ribavirin has shown effectiveness if administered early in the course of the illness.
Preventing Lassa Fever primarily involves reducing contact with the Mastomys rodent population and implementing effective infection control practices. This includes storing food in rodent-proof containers, maintaining clean households, and using traps to reduce rodent populations. In healthcare settings, strict barrier nursing techniques, such as using protective clothing and proper disposal of medical waste, are crucial to prevent nosocomial infections.
""Lassa Fever- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Lassa Fever pipeline landscape is provided which includes the disease overview and Lassa Fever treatment guidelines. The assessment part of the report embraces, in depth Lassa Fever commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Lassa Fever collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Lassa Fever R&D. The therapies under development are focused on novel approaches to treat/improve Lassa Fever.
This segment of the Lassa Fever report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Lassa Fever Emerging Drugs
- ARN-75039: Arisan Therapeutics
Further product details are provided in the report……..
Lassa Fever: Therapeutic Assessment
This segment of the report provides insights about the different Lassa Fever drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Lassa Fever
- There are approx. 3+ key companies which are developing the therapies for Lassa Fever. The companies which have their Lassa Fever drug candidates in the most advanced stage, i.e. Phase I include, Arisan Therapeutics.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Lassa Fever: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Lassa Fever therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Lassa Fever drugs.
Lassa Fever Report Insights
- Lassa Fever Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Lassa Fever drugs?
- How many Lassa Fever drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Lassa Fever?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Lassa Fever therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Lassa Fever and their status?
- What are the key designations that have been granted to the emerging drugs?
- Arisan Therapeutics
- Imunon
- ARN-75039
- IMNN-102
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Lassa Fever: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Lassa Fever– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- ARN-75039: Arisan Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Lassa Fever Key Companies
- Lassa Fever Key Products
- Lassa Fever- Unmet Needs
- Lassa Fever- Market Drivers and Barriers
- Lassa Fever- Future Perspectives and Conclusion
- Lassa Fever Analyst Views
- Lassa Fever Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
